. 2019 May 24;14(5):e0216828. doi: 10.1371/journal.pone.0216828

Table 2. Univariate and multivariate Cox regression analyses of mortality in patients with unresectable/metastatic HCC.

Variable	Crude HR (95% CI)	P	Adjusted HR (95% CI)	P
Propranolol
With	0.77 (0.72–0.83)	<0.001^*	0.78 (0.72–0.84)	<0.001^*
Without	Reference 1.00	<0.001^*	Reference 1.00	<0.001^*
Propranolol
<545 days	0.81 (0.73–0.99)	0.04^*	0.81 (0.74–0.99)	0.045^*
545–730 days	0.77 (0.70–0.83)	0.001^*	0.78 (0.71–0.84)	0.002^*
>730 days	0.69 (0.58–0.79)	<0.001^*	0.70 (0.59–0.80)	<0.001^*
Without	Reference 1.00		Reference 1.00
Sex
Male	1.20 (1.10–1.29)	<0.001^*	1.14 (1.05–1.24)	<0.001^*
Female	Reference 1.00	<0.001^*	Reference 1.00	<0.001^*
Age group (years)
≥65	1.41 (1.27–1.56)	<0.001^*	1.13 (1.06–1.88)	<0.001^*
50–64	1.24 (1.15–1.34)	<0.001^*	1.09 (1.01–1.29)	0.03^*
20–49	Reference 1.00		Reference 1.00
HBV infection
With	1.09 (1.01–1.20)	0.04^*	1.08 (1.01–1.18)	0.04^*
Without	Reference 1.00	0.04^*	Reference 1.00	0.04^*
HCV infection
With	1.45 (1.29–1.63)	<0.001^*	1.36 (1.17–1.50)	<0.001^*
Without	Reference 1.00	<0.001^*	Reference 1.00	<0.001^*
Alcoholic liver disease
With	1.04 (0.91–1.20)	0.56	1.08 (0.76–1.12)	0.10
Without	Reference 1.00	0.56	Reference 1.00	0.10
Liver cirrhosis
With	1.07 (1.01–1.15)	0.045^*	1.06 (0.99–1.15)	0.12
Without	Reference 1.00	0.045^*	Reference 1.00	0.12
Renal failure
With	1.12 (0.94–1.33)	0.21	1.11 (0.94–1.32)	0.23
Without	Reference 1.00	0.21	Reference 1.00	0.23
DM
With	1.01 (0.83–1.00)	0.05	1.07 (0.89–1.08)	0.46
Without	Reference 1.00	0.05	Reference 1.00	0.46
HTN
With	1.81 (1.74–1.90)	<0.001^*	1.01 (0.82–1.01)	0.08
Without	Reference 1.00	<0.001^*	Reference 1.00	0.08
CAD
With	1.00 (0.79–1.25)	0.95	1.07 (0.86–1.37)	0.49
Without	Reference 1.00	0.95	Reference 1.00	0.49
CCI_R	1.05 (1.02–1.09)	0.001^*	1.03 (0.99–1.06)	0.12
Aspirin
With	1.27 (0.64–1.91)	0.45	1.25 (0.66–1.97)	0.45
Without	Reference 1.00	0.45	Reference 1.00	0.45
Statins
With	1.14 (0.88–1.80)	0.29	1.11 (0.83–1.86)	0.30
Without	Reference 1.00	0.29	Reference 1.00	0.30
Metformin
With	1.10 (0.75–1.39)	0.34	1.10 (0.77–1.34)	0.34
Without	Reference 1.00	0.34	Reference 1.00	0.34
Fibrates
With	1.45 (0.67–2.19)	0.39	1.35 (0.67–2.03)	0.40
Without	Reference 1.00	0.39	Reference 1.00	0.40
TZDs
With	1.20 (0.52–1.60)	0.48	1.12 (0.50–1.60)	0.48
Without	Reference 1.00	0.48	Reference 1.00	0.48
ACEIs
With	1.10 (0.83–1.56)	0.67	1.08 (0.85–1.46)	0.60
Without	Reference 1.00	0.67	Reference 1.00	0.60

*Significantly correlated with outcome, P-value < 0.05. HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; DM, diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; CCI_R, Charlson comorbidity index after removal of the above mentioned comorbidities; TZDs, thiazolidinediones; ACEIs, angiotensin-converting enzyme inhibitors